Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 1/2018

01-02-2018

Alopecia Areata: a Comprehensive Review of Pathogenesis and Management

Authors: Ralph M. Trüeb, Maria Fernanda Reis Gavazzoni Dias

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2018

Login to get access

Abstract

Alopecia areata is a common hair loss condition that is characterized by acute onset of non-scarring hair loss in usually sharply defined areas ranging from small patches to extensive or less frequently diffuse involvement. Depending on its acuity and extent, hair loss is an important cause of anxiety and disability. The current understanding is that the condition represents an organ-specific autoimmune disease of the hair follicle with a genetic background. Genome-wide association studies provide evidence for the involvement of both innate and acquired immunity in the pathogenesis, and mechanistic studies in mouse models of alopecia areata have specifically implicated an IFN-γ-driven immune response, including IFNγ, IFNγ-induced chemokines and cytotoxic CD8 T cells as the main drivers of disease pathogenesis. A meta-analysis of published trials on treatment of alopecia areata states that only few treatments have been well evaluated in randomized trials. Nevertheless, depending on patient age, affected surface area and disease duration, an empiric treatment algorithm can be designed with corticosteroids and topical immunotherapy remaining the mainstay of therapy. The obviously limited success of evidence-based therapies points to a more important complexity of hair loss. At the same time, the complexity of pathogenesis offers opportunities for the development of novel targeted therapies. New treatment opportunities based on the results of genome-wide association studies that implicate T cell and natural killer cell activation pathways are paving the way to new approaches in future clinical trials. Currently, there are ongoing studies with the CTLA4-Ig fusion protein abatacept, anti-IL15Rβ monoclonal antibodies and the Janus kinase inhibitors tofacitinib, ruxolitinib and baricitinib. Ultimately, the options available for adapting to the disease rather than treating it in an effort to cure may also be taken into consideration in selected cases of long-standing or recurrent small spot disease.
Literature
1.
go back to reference Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. (1995) Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70(7):628–633PubMedCrossRef Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. (1995) Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70(7):628–633PubMedCrossRef
2.
go back to reference Muller SA, Winkelmann RK (1963) Alopecia areata. An evaluation of 736 patients. Arch Dermatol 88:290–297PubMedCrossRef Muller SA, Winkelmann RK (1963) Alopecia areata. An evaluation of 736 patients. Arch Dermatol 88:290–297PubMedCrossRef
3.
go back to reference Finner AM (2011) Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther 24(3):348–354PubMedCrossRef Finner AM (2011) Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther 24(3):348–354PubMedCrossRef
4.
go back to reference Safavi K (1992) Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 128(5):702PubMedCrossRef Safavi K (1992) Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 128(5):702PubMedCrossRef
5.
go back to reference Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E (2009) Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol 23(5):572–573PubMedCrossRef Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E (2009) Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol 23(5):572–573PubMedCrossRef
6.
go back to reference Inui S, Nakajima T, Nakagawa K, Itami S (2008) Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol 47(7):688–693PubMedCrossRef Inui S, Nakajima T, Nakagawa K, Itami S (2008) Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol 47(7):688–693PubMedCrossRef
7.
go back to reference Delorenze LM, Gavazzoni-Dias MFR, Teixeira MS, Aide MK (2016) Concentric polycyclic regrowth pattern in alopecia areata. Int J Trichol 8(1):35–37CrossRef Delorenze LM, Gavazzoni-Dias MFR, Teixeira MS, Aide MK (2016) Concentric polycyclic regrowth pattern in alopecia areata. Int J Trichol 8(1):35–37CrossRef
8.
go back to reference Elston DM, Clayton AS, Meffert JJ, McCollough ML (2000) Migratory poliosis: a forme fruste of alopecia areata? J Am Acad Dermatol 42(6):1076–1077PubMedCrossRef Elston DM, Clayton AS, Meffert JJ, McCollough ML (2000) Migratory poliosis: a forme fruste of alopecia areata? J Am Acad Dermatol 42(6):1076–1077PubMedCrossRef
9.
go back to reference Tosti A, Morelli R, Bardazzi F, Peluso AM (1994) Prevalence of nail abnormalities in children with alopecia areata. Pediatr Dermatol 11(2):112–115PubMedCrossRef Tosti A, Morelli R, Bardazzi F, Peluso AM (1994) Prevalence of nail abnormalities in children with alopecia areata. Pediatr Dermatol 11(2):112–115PubMedCrossRef
10.
go back to reference Sharma VK, Dawn G, Muralidhar S, Kumar B (1998) Nail changes in 1000 Indian patients with alopecia areata. J Eur Acad Dermatol Venereol 10(2):189–191PubMedCrossRef Sharma VK, Dawn G, Muralidhar S, Kumar B (1998) Nail changes in 1000 Indian patients with alopecia areata. J Eur Acad Dermatol Venereol 10(2):189–191PubMedCrossRef
11.
go back to reference Kasumagic-Halilovic E, Prohic A (2009) Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 23(2):240–241PubMedCrossRef Kasumagic-Halilovic E, Prohic A (2009) Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 23(2):240–241PubMedCrossRef
13.
go back to reference Tosti A, Fanti PA, Morelli R, Bardazzi F (1991) Trachyonychia associated with alopecia areata: a clinical and pathologic study. J Am Acad Dermatol 25(2 Pt 1):266–270PubMedCrossRef Tosti A, Fanti PA, Morelli R, Bardazzi F (1991) Trachyonychia associated with alopecia areata: a clinical and pathologic study. J Am Acad Dermatol 25(2 Pt 1):266–270PubMedCrossRef
14.
go back to reference Tosti A, Bardazzi F, Piraccini BM, Fanti PA, Cameli N, Pileri S (1995) Is trachyonychia, a variety of alopecia areata, limited to the nails? J Invest Dermatol 104(5 Suppl):27S–28SPubMedCrossRef Tosti A, Bardazzi F, Piraccini BM, Fanti PA, Cameli N, Pileri S (1995) Is trachyonychia, a variety of alopecia areata, limited to the nails? J Invest Dermatol 104(5 Suppl):27S–28SPubMedCrossRef
15.
go back to reference Dotz WI, Lieber CD, Vogt PJ (1985) Leukonychia punctata and pitted nails in alopecia areata. Arch Dermatol 121(11):1452–1454PubMedCrossRef Dotz WI, Lieber CD, Vogt PJ (1985) Leukonychia punctata and pitted nails in alopecia areata. Arch Dermatol 121(11):1452–1454PubMedCrossRef
16.
go back to reference Shelley WB (1980) The spotted lunula. A neglected nail sign associated with alopecia areata. J Am Acad Dermatol 2(5):385–387PubMedCrossRef Shelley WB (1980) The spotted lunula. A neglected nail sign associated with alopecia areata. J Am Acad Dermatol 2(5):385–387PubMedCrossRef
17.
go back to reference Bergner T, Donhauser G, Ruzicka T (1992) Red lunulae in severe alopecia areata. Acta Derm Venereol 72(3):203–205PubMed Bergner T, Donhauser G, Ruzicka T (1992) Red lunulae in severe alopecia areata. Acta Derm Venereol 72(3):203–205PubMed
18.
go back to reference Tosti A, Pazzaglia M, Venturi M, Chiacchio NC Jr (2013) Severe onycholysis in a card illusionist with alopecia areata universalis. Int J Trichol 5(2):81–82CrossRef Tosti A, Pazzaglia M, Venturi M, Chiacchio NC Jr (2013) Severe onycholysis in a card illusionist with alopecia areata universalis. Int J Trichol 5(2):81–82CrossRef
19.
go back to reference Horn RT Jr, Odom RB (1980) Twenty-nail dystrophy of alopecia areata. Arch Dermatol 116(5):573–574PubMedCrossRef Horn RT Jr, Odom RB (1980) Twenty-nail dystrophy of alopecia areata. Arch Dermatol 116(5):573–574PubMedCrossRef
20.
go back to reference De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD (1989) Juvenile versus maturity-onset alopecia areata—a comparative retrospective clinical study. Clin Exp Dermatol 14(6):429–433PubMedCrossRef De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD (1989) Juvenile versus maturity-onset alopecia areata—a comparative retrospective clinical study. Clin Exp Dermatol 14(6):429–433PubMedCrossRef
21.
go back to reference Sato-Kawamura M, Aiba S, Tagami H (2002) Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis. Dermatology 205(4):367–373PubMedCrossRef Sato-Kawamura M, Aiba S, Tagami H (2002) Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis. Dermatology 205(4):367–373PubMedCrossRef
22.
go back to reference Lew BL, Shin MK, Sim WY (2009) Acute diffuse and total alopecia: a new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol 60(1):85–93PubMedCrossRef Lew BL, Shin MK, Sim WY (2009) Acute diffuse and total alopecia: a new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol 60(1):85–93PubMedCrossRef
23.
go back to reference Braun-Falco O, Zaun H (1962) Über die Beteiligung des gesamten Capillitiums bei Alopecia areata. Hautarzt 13:342–348 Braun-Falco O, Zaun H (1962) Über die Beteiligung des gesamten Capillitiums bei Alopecia areata. Hautarzt 13:342–348
24.
25.
go back to reference Navarini AA, Nobbe S, Trüeb RM (2009) Marie Antoinette syndrome. Arch Dermatol 145(6):65CrossRef Navarini AA, Nobbe S, Trüeb RM (2009) Marie Antoinette syndrome. Arch Dermatol 145(6):65CrossRef
26.
go back to reference Goldenhersh MA (1992) Rapid whitening of the hair first reported in the Talmud: possible mechanisms of this intriguing phenomenon. Am J Dermatopathol 14:367–368PubMedCrossRef Goldenhersh MA (1992) Rapid whitening of the hair first reported in the Talmud: possible mechanisms of this intriguing phenomenon. Am J Dermatopathol 14:367–368PubMedCrossRef
28.
go back to reference Hoffmann E (1957) Sudden turning gray of the hair caused by fright, canities subita psychogenica. Z Haut Geschlechtskr 22:74–78PubMed Hoffmann E (1957) Sudden turning gray of the hair caused by fright, canities subita psychogenica. Z Haut Geschlechtskr 22:74–78PubMed
30.
go back to reference Metchnikoff E (1901) On the process of hair turning white. Proc R Soc Lond 69:156CrossRef Metchnikoff E (1901) On the process of hair turning white. Proc R Soc Lond 69:156CrossRef
31.
go back to reference Guin JD, Kumar V, Petersen BH (1981) Immunofluorescence findings in rapid whitening of scalp hair. Arch Dermatol 117:576–578PubMedCrossRef Guin JD, Kumar V, Petersen BH (1981) Immunofluorescence findings in rapid whitening of scalp hair. Arch Dermatol 117:576–578PubMedCrossRef
32.
go back to reference Helm F, Milgrom H (1970) Can scalp hair suddenly turn white? A case of canities subita. Arch Dermatol 102:102–103PubMedCrossRef Helm F, Milgrom H (1970) Can scalp hair suddenly turn white? A case of canities subita. Arch Dermatol 102:102–103PubMedCrossRef
33.
go back to reference Paus R, Slominski A, Czarnetzki BM (1993) Is alopecia areata, an autoimmune response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 66:541–554PubMedPubMedCentral Paus R, Slominski A, Czarnetzki BM (1993) Is alopecia areata, an autoimmune response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 66:541–554PubMedPubMedCentral
34.
go back to reference McBride AK, Bergfeld WF (1990) Mosaic hair color changes in alopecia areata. Cleve Clin J Med 157:354–356CrossRef McBride AK, Bergfeld WF (1990) Mosaic hair color changes in alopecia areata. Cleve Clin J Med 157:354–356CrossRef
35.
go back to reference Xavier S (1934) Sudden blanching of the hair as described in literature. Chron Med 41:116–120 Xavier S (1934) Sudden blanching of the hair as described in literature. Chron Med 41:116–120
36.
go back to reference Navarini AA, Trüeb RM (2010) Why Henry III of Navarre’s hair probably did not turn white overnight. Int J Trichol 2:2–4CrossRef Navarini AA, Trüeb RM (2010) Why Henry III of Navarre’s hair probably did not turn white overnight. Int J Trichol 2:2–4CrossRef
37.
go back to reference Muller SA, Winkelmann RK (1963) Alopecia areata. Arch Dermatol:290–297 Muller SA, Winkelmann RK (1963) Alopecia areata. Arch Dermatol:290–297
38.
go back to reference DeWeert K, Temmerman L, Kint A (1984) Alopecia areata. A clinical study. Dermatologica 168:224–229CrossRef DeWeert K, Temmerman L, Kint A (1984) Alopecia areata. A clinical study. Dermatologica 168:224–229CrossRef
39.
go back to reference De Waard van der Spek FB, Oranje AP, De-Raeymaecker DM, Peereboom-Wynia JDR (1989) Junvenile versus maturity-onset alopecia areata: a comparative retrospective clinical study. Clin Exp Dermatol 14:429–433PubMedCrossRef De Waard van der Spek FB, Oranje AP, De-Raeymaecker DM, Peereboom-Wynia JDR (1989) Junvenile versus maturity-onset alopecia areata: a comparative retrospective clinical study. Clin Exp Dermatol 14:429–433PubMedCrossRef
40.
go back to reference an der Steen P, Traupe H, Happle R, Boezeman J, Strater R, Hamm H (1992) The genetic risk for alopecia areata in first degree relatives of severely affected patients: an estimate. Acta Derm Venerol 72:373–375PubMed an der Steen P, Traupe H, Happle R, Boezeman J, Strater R, Hamm H (1992) The genetic risk for alopecia areata in first degree relatives of severely affected patients: an estimate. Acta Derm Venerol 72:373–375PubMed
41.
go back to reference Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM (2007) Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 80:316–328PubMedPubMedCentralCrossRef Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM (2007) Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 80:316–328PubMedPubMedCentralCrossRef
42.
go back to reference Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M (1998) Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Derm 38:418–425PubMedCrossRef Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M (1998) Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Derm 38:418–425PubMedCrossRef
43.
go back to reference Price VH, Colombe BW (1996) Heritable factors distinguish two types of alopecia areata. Dermatol Clin 14(4):679–689PubMedCrossRef Price VH, Colombe BW (1996) Heritable factors distinguish two types of alopecia areata. Dermatol Clin 14(4):679–689PubMedCrossRef
44.
go back to reference Paus R, Ito N, Takigawa M, Ito T (2003) The hair follicle and immune privilege. J Investig Dermatol Symp Proc 8(2):188–194PubMedCrossRef Paus R, Ito N, Takigawa M, Ito T (2003) The hair follicle and immune privilege. J Investig Dermatol Symp Proc 8(2):188–194PubMedCrossRef
45.
go back to reference Paus R, Bertolini M (2013) The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. Investig Dermatol Symp Proc 16(1):S25–S27CrossRef Paus R, Bertolini M (2013) The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. Investig Dermatol Symp Proc 16(1):S25–S27CrossRef
46.
go back to reference Dressel D, Brütt CH, Manfras B, Zollner TM, Wunderlich A, Böhm BO, Boehncke W (1997) Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T-cell receptor-repertoire among infiltrating lymphocytes. J Cutan Pathol 24(3):164–168PubMedCrossRef Dressel D, Brütt CH, Manfras B, Zollner TM, Wunderlich A, Böhm BO, Boehncke W (1997) Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T-cell receptor-repertoire among infiltrating lymphocytes. J Cutan Pathol 24(3):164–168PubMedCrossRef
47.
go back to reference Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ (1968) Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 80(3):135–139PubMedCrossRef Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ (1968) Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 80(3):135–139PubMedCrossRef
48.
go back to reference Cunliffe WJ, Hall R, Stevenson CJ, Weightman D (1969) Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol 81(12):877–881PubMedCrossRef Cunliffe WJ, Hall R, Stevenson CJ, Weightman D (1969) Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol 81(12):877–881PubMedCrossRef
49.
go back to reference Puavilai S, Puavilai G, Charuwichitratana S, Sakuntabhai A, Sriprachya-Anunt S (1994) Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 33(9):632–633PubMedCrossRef Puavilai S, Puavilai G, Charuwichitratana S, Sakuntabhai A, Sriprachya-Anunt S (1994) Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 33(9):632–633PubMedCrossRef
50.
go back to reference Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A (2005) Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol 5:11PubMedPubMedCentralCrossRef Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A (2005) Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol 5:11PubMedPubMedCentralCrossRef
51.
go back to reference Krishnaram AS, Saigal A, Adityan B (2013) Alopecia areata—vitiligo overlap syndrome: an emerging clinical variant. Indian J Dermatol Venereol Leprol. 79(4):535–537PubMedCrossRef Krishnaram AS, Saigal A, Adityan B (2013) Alopecia areata—vitiligo overlap syndrome: an emerging clinical variant. Indian J Dermatol Venereol Leprol. 79(4):535–537PubMedCrossRef
52.
go back to reference Walker A, Mesinkovska NA, Boncher J, Tamburro J, Bergfeld WF (2015) Colocalization of vitiligo and alopecia areata presenting as poliosis. J Cutan Pathol 42(2):150–154PubMedCrossRef Walker A, Mesinkovska NA, Boncher J, Tamburro J, Bergfeld WF (2015) Colocalization of vitiligo and alopecia areata presenting as poliosis. J Cutan Pathol 42(2):150–154PubMedCrossRef
54.
go back to reference Kumar B, Sharma VK, Sehgal S (1995) Antismooth muscle and antiparietal cell antibodies in Indians with alopecia areata. Int J Dermatol 34(8):542–545PubMedCrossRef Kumar B, Sharma VK, Sehgal S (1995) Antismooth muscle and antiparietal cell antibodies in Indians with alopecia areata. Int J Dermatol 34(8):542–545PubMedCrossRef
55.
go back to reference Tobin DJ, Orentreich N, Fenton DA, Bystryn JC (1994) Antibodies to hair follicles in alopecia areata. J Invest Dermatol 102(5):721–724PubMedCrossRef Tobin DJ, Orentreich N, Fenton DA, Bystryn JC (1994) Antibodies to hair follicles in alopecia areata. J Invest Dermatol 102(5):721–724PubMedCrossRef
56.
go back to reference Tobin DJ (2003) Characterization of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc 8(2):176–181PubMedCrossRef Tobin DJ (2003) Characterization of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc 8(2):176–181PubMedCrossRef
57.
go back to reference Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS (1998) Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 101(1):62–67PubMedPubMedCentralCrossRef Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS (1998) Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 101(1):62–67PubMedPubMedCentralCrossRef
58.
go back to reference Sundberg JP, Silva KA, Li R, Cox GA, King LE (2004) Adult-onset alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Derm 123:294–297PubMedCrossRef Sundberg JP, Silva KA, Li R, Cox GA, King LE (2004) Adult-onset alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Derm 123:294–297PubMedCrossRef
59.
go back to reference Tobin DJ, Sundberg JP, King LE Jr, Boggess D, Bystryn JC (1997) Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol 109(3):329–333PubMedCrossRef Tobin DJ, Sundberg JP, King LE Jr, Boggess D, Bystryn JC (1997) Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol 109(3):329–333PubMedCrossRef
60.
go back to reference Koca R, Armutcu F, Altinyazar C, Gürel A (2005) Evaluation of lipid peroxidation, oxidant/antioxidant status, and serum nitric oxide levels in alopecia areata. Med Sci Monit 11(6):CR296–CR299PubMed Koca R, Armutcu F, Altinyazar C, Gürel A (2005) Evaluation of lipid peroxidation, oxidant/antioxidant status, and serum nitric oxide levels in alopecia areata. Med Sci Monit 11(6):CR296–CR299PubMed
61.
go back to reference Bakry OA, Elshazly RM, Shoeib MA, Gooda A (2014) Oxidative stress in alopecia areata: a case-control study. Am J Clin Dermatol 15(1):57–64PubMedCrossRef Bakry OA, Elshazly RM, Shoeib MA, Gooda A (2014) Oxidative stress in alopecia areata: a case-control study. Am J Clin Dermatol 15(1):57–64PubMedCrossRef
62.
go back to reference Prie BE, Voiculescu VM, Ionescu-Bozdog OB, Petrutescu B, Iosif L, Gaman LE, Clatici VG, Stoian I, Giurcaneanu C (2015) Oxidative stress and alopecia areata. J Med Life 8:43–46PubMedPubMedCentral Prie BE, Voiculescu VM, Ionescu-Bozdog OB, Petrutescu B, Iosif L, Gaman LE, Clatici VG, Stoian I, Giurcaneanu C (2015) Oxidative stress and alopecia areata. J Med Life 8:43–46PubMedPubMedCentral
63.
go back to reference Yenin JZ, Serarslan G, Yönden Z, Ulutaş KT (2015) Investigation of oxidative stress in patients with alopecia areata and its relationship with disease severity, duration, recurrence and pattern. Clin Exp Dermatol 40(6):617–621PubMedCrossRef Yenin JZ, Serarslan G, Yönden Z, Ulutaş KT (2015) Investigation of oxidative stress in patients with alopecia areata and its relationship with disease severity, duration, recurrence and pattern. Clin Exp Dermatol 40(6):617–621PubMedCrossRef
64.
go back to reference Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV, Meyer KC, Paus R, Jahoda CA, Amos CI, Gregersen PK, Christiano AM (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466:113–117PubMedPubMedCentralCrossRef Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV, Meyer KC, Paus R, Jahoda CA, Amos CI, Gregersen PK, Christiano AM (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466:113–117PubMedPubMedCentralCrossRef
65.
go back to reference Skinner RB Jr, Light WH, Leonardi C, Bale GF, Rosenberg EW (1995) A molecular approach to alopecia areata. J Invest Dermatol 104(5 Suppl):3S–4SPubMedCrossRef Skinner RB Jr, Light WH, Leonardi C, Bale GF, Rosenberg EW (1995) A molecular approach to alopecia areata. J Invest Dermatol 104(5 Suppl):3S–4SPubMedCrossRef
66.
go back to reference Tosti A, La Placa M, Placucci F, Gentilomi G, Venturoli S, Zerbini M, Musiani M (1996) No correlation between cytomegalovirus and alopecia areata. J Invest Dermatol 107(3):443PubMedCrossRef Tosti A, La Placa M, Placucci F, Gentilomi G, Venturoli S, Zerbini M, Musiani M (1996) No correlation between cytomegalovirus and alopecia areata. J Invest Dermatol 107(3):443PubMedCrossRef
67.
go back to reference García-Hernández MJ, Torres MJ, Palomares JC, Rodríguez-Pichardo A, Aznar J, Camacho F (1998) No evidence of cytomegalovirus DNA in alopecia areata. J Invest Dermatol 110(2):185PubMedCrossRef García-Hernández MJ, Torres MJ, Palomares JC, Rodríguez-Pichardo A, Aznar J, Camacho F (1998) No evidence of cytomegalovirus DNA in alopecia areata. J Invest Dermatol 110(2):185PubMedCrossRef
68.
go back to reference Offidani A, Amerio P, Bernardini ML, Feliciani C, Bossi G (2000) Role of cytomegalovirus replication in alopecia areata pathogenesis. J Cutan Med Surg 4(2):63–65PubMedCrossRef Offidani A, Amerio P, Bernardini ML, Feliciani C, Bossi G (2000) Role of cytomegalovirus replication in alopecia areata pathogenesis. J Cutan Med Surg 4(2):63–65PubMedCrossRef
69.
go back to reference Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A et al (2015) Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 22(6):5966CrossRef Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A et al (2015) Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 22(6):5966CrossRef
70.
go back to reference Alli R, Nguyen P, Boyd K, Sundberg JP, Geiger TL (2012) A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J Immunol 188(1):477–486PubMedCrossRef Alli R, Nguyen P, Boyd K, Sundberg JP, Geiger TL (2012) A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J Immunol 188(1):477–486PubMedCrossRef
71.
go back to reference Fischer J, Degenhardt F, Hofmann A, Redler S, Basmanav FB, Heilmann-Heimbach S, Hanneken S, Giehl KA Wolff H, Moebus S, Kruse R, Lutz G, Blaumeiser B, Böhm M, Garcia Bartels N, Blume-Peytavi U, Petukhova L, Christiano AM, Nöthen MM, Betz R 2016. Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. Exp Dermatol. 16 Fischer J, Degenhardt F, Hofmann A, Redler S, Basmanav FB, Heilmann-Heimbach S, Hanneken S, Giehl KA Wolff H, Moebus S, Kruse R, Lutz G, Blaumeiser B, Böhm M, Garcia Bartels N, Blume-Peytavi U, Petukhova L, Christiano AM, Nöthen MM, Betz R 2016. Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. Exp Dermatol. 16
72.
go back to reference Feinstain AR (1970) The pr-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 23(7):455–468CrossRef Feinstain AR (1970) The pr-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 23(7):455–468CrossRef
73.
go back to reference Brown AC, Olkowski ZL, McLaren JR, Kutner MH (1977) Alopecia areata and vitiligo associated with Down’s syndrome. (Letter) ArchDerm 113:1296 Brown AC, Olkowski ZL, McLaren JR, Kutner MH (1977) Alopecia areata and vitiligo associated with Down’s syndrome. (Letter) ArchDerm 113:1296
75.
go back to reference Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN (2011) Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol 65(5):949–956PubMedCrossRef Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN (2011) Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol 65(5):949–956PubMedCrossRef
76.
go back to reference Lee NR, Kim BK, Yoon NY, Lee SY, Ahn SY, Lee WS (2014) Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients. Ann Dermatol 26(6):722–726PubMedPubMedCentralCrossRef Lee NR, Kim BK, Yoon NY, Lee SY, Ahn SY, Lee WS (2014) Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients. Ann Dermatol 26(6):722–726PubMedPubMedCentralCrossRef
77.
go back to reference Barahmani N, Schabath MB, Duvic M, National Alopecia Areata Registry (2009) History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 61(4):581–591PubMedCrossRef Barahmani N, Schabath MB, Duvic M, National Alopecia Areata Registry (2009) History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 61(4):581–591PubMedCrossRef
78.
go back to reference Mohan GC, Silverberg JI (2015) Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol 151(5):522–528PubMedCrossRef Mohan GC, Silverberg JI (2015) Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol 151(5):522–528PubMedCrossRef
79.
go back to reference Corazza GR, Andreani ML, Venturo N et al (1995) Celiac disease and alopecia areata: report of a new association. Gastroenterology 109(4):1333–1337PubMedCrossRef Corazza GR, Andreani ML, Venturo N et al (1995) Celiac disease and alopecia areata: report of a new association. Gastroenterology 109(4):1333–1337PubMedCrossRef
80.
go back to reference Bondavalli P, Quadri G, Parodi A, Rebora A (1998) Failure of gluten-free diet in celiac disease-associated alopecia areata. Acta Derm Venereol 78(4):319PubMedCrossRef Bondavalli P, Quadri G, Parodi A, Rebora A (1998) Failure of gluten-free diet in celiac disease-associated alopecia areata. Acta Derm Venereol 78(4):319PubMedCrossRef
81.
go back to reference Naveh Y, Rosenthal E, Ben-Arieh Y, Etzioni A (1999) Celiac disease-associated alopecia in childhood. J Pediatr 134(3):362–364PubMedCrossRef Naveh Y, Rosenthal E, Ben-Arieh Y, Etzioni A (1999) Celiac disease-associated alopecia in childhood. J Pediatr 134(3):362–364PubMedCrossRef
82.
go back to reference Viola F, Barbato M, Formisano M et al (1999) Reappearance of alopecia areata in a coeliac patient during an unintentional challenge with gluten. Minerva Gastroenterol Dietol 45(4):283–285PubMed Viola F, Barbato M, Formisano M et al (1999) Reappearance of alopecia areata in a coeliac patient during an unintentional challenge with gluten. Minerva Gastroenterol Dietol 45(4):283–285PubMed
83.
go back to reference Bardella MT, Marino R, Barbareschi M et al (2000) Alopecia areata and coeliac disease: no effect of a gluten-free diet on hair growth. Dermatology 2:108–110CrossRef Bardella MT, Marino R, Barbareschi M et al (2000) Alopecia areata and coeliac disease: no effect of a gluten-free diet on hair growth. Dermatology 2:108–110CrossRef
84.
go back to reference Fessatou S, Kostaki M, Karpathios T (2003) Coeliac disease and alopecia areata in childhood. J Paediatr Child Health 39(2):152–154PubMedCrossRef Fessatou S, Kostaki M, Karpathios T (2003) Coeliac disease and alopecia areata in childhood. J Paediatr Child Health 39(2):152–154PubMedCrossRef
85.
go back to reference Zampetti M, Filippetti R (2008) Alopecia areata and celiac disease. G Ital Dermatol Venereol 143(2):168PubMed Zampetti M, Filippetti R (2008) Alopecia areata and celiac disease. G Ital Dermatol Venereol 143(2):168PubMed
87.
go back to reference Kantor J, Kessler LJ, Brooks DG, Cotsarelis G (2003) Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 121(5):985–988PubMedCrossRef Kantor J, Kessler LJ, Brooks DG, Cotsarelis G (2003) Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 121(5):985–988PubMedCrossRef
88.
go back to reference Park H, Kim CW, Kim SS, Park CW (2009) The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. Ann Dermatol 21:142–146PubMedPubMedCentralCrossRef Park H, Kim CW, Kim SS, Park CW (2009) The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. Ann Dermatol 21:142–146PubMedPubMedCentralCrossRef
89.
go back to reference Bhat YJ, Manzoor S, Khan AR, Qayoom S (2009) Trace element levels in alopecia areata. Indian J Dermatol Venereol Leprol 75(1):29–31PubMedCrossRef Bhat YJ, Manzoor S, Khan AR, Qayoom S (2009) Trace element levels in alopecia areata. Indian J Dermatol Venereol Leprol 75(1):29–31PubMedCrossRef
90.
go back to reference Abdel Fattah NS, Atef MM, Al-Qaradaghi SM (2016) Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata. Int J Dermatol 55(1):24–29PubMedCrossRef Abdel Fattah NS, Atef MM, Al-Qaradaghi SM (2016) Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata. Int J Dermatol 55(1):24–29PubMedCrossRef
91.
go back to reference Jin W, Zheng H, Shan B, Wu Y 2017. Changes of serum trace elements level in patients with alopecia areata: ameta-analysis. J Dermatol 2 Jin W, Zheng H, Shan B, Wu Y 2017. Changes of serum trace elements level in patients with alopecia areata: ameta-analysis. J Dermatol 2
92.
go back to reference Yilmaz N, Serarslan G, Gokce C (2012) Vitamin D concentration are decreased in patients with alopecia areata. Vitam Trace Elem 1:105–109CrossRef Yilmaz N, Serarslan G, Gokce C (2012) Vitamin D concentration are decreased in patients with alopecia areata. Vitam Trace Elem 1:105–109CrossRef
93.
go back to reference d’Ovidio R, Vessio M, d’Ovidio FD (2013) Reduced level of 25-hydroxyvitamin D in chronic/relapsing alopecia areata. Dermatoendocrinol 5(2):271–273PubMedPubMedCentralCrossRef d’Ovidio R, Vessio M, d’Ovidio FD (2013) Reduced level of 25-hydroxyvitamin D in chronic/relapsing alopecia areata. Dermatoendocrinol 5(2):271–273PubMedPubMedCentralCrossRef
94.
go back to reference Aksu Cerman A, Sarikaya Solak S, Kivanc AI (2014) Vitamin D deficiency in alopecia areata. Br J Dermatol 170(6):1299–1304PubMedCrossRef Aksu Cerman A, Sarikaya Solak S, Kivanc AI (2014) Vitamin D deficiency in alopecia areata. Br J Dermatol 170(6):1299–1304PubMedCrossRef
95.
96.
go back to reference Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J (2008) Interventions for alopecia areata. Cochrane Database Syst Rev 16(2):CD004413 Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J (2008) Interventions for alopecia areata. Cochrane Database Syst Rev 16(2):CD004413
97.
go back to reference Collins SM, Dominguez M, Ilmarinen T, Costigan C, Irvine AD (2006) Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 154(6):1088–1093PubMedCrossRef Collins SM, Dominguez M, Ilmarinen T, Costigan C, Irvine AD (2006) Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 154(6):1088–1093PubMedCrossRef
98.
go back to reference Finnish-German APECED Consortium (1997) An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 17:399–403CrossRef Finnish-German APECED Consortium (1997) An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 17:399–403CrossRef
99.
go back to reference Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJE, Lalioti MD, Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S, Ito F, Shimizu N (1997) Positional cloning of the APECED gene. Nat Genet 17:393–398PubMedCrossRef Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJE, Lalioti MD, Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S, Ito F, Shimizu N (1997) Positional cloning of the APECED gene. Nat Genet 17:393–398PubMedCrossRef
100.
go back to reference Betterle C, Greggio NA, Volpato M (1998) Autoimmune polyglandular syndrome type 1. J Clin Endocr Metab 83:1049–1055PubMedCrossRef Betterle C, Greggio NA, Volpato M (1998) Autoimmune polyglandular syndrome type 1. J Clin Endocr Metab 83:1049–1055PubMedCrossRef
101.
go back to reference Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, et al. 2016 Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 1(13) Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, et al. 2016 Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 1(13)
102.
go back to reference Rodriguez TA, Duvic M, National Alopecia Areata Registry (2008) Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol 59(1):137–139PubMedCrossRef Rodriguez TA, Duvic M, National Alopecia Areata Registry (2008) Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol 59(1):137–139PubMedCrossRef
103.
go back to reference Chu CH, Cheng YP, Chan JY (2016) Alopecia areata after vaccination: recurrence with rechallenge. Pediatr Dermatol 33(3):e218–e219PubMedCrossRef Chu CH, Cheng YP, Chan JY (2016) Alopecia areata after vaccination: recurrence with rechallenge. Pediatr Dermatol 33(3):e218–e219PubMedCrossRef
104.
go back to reference Stewart MI, Smoller BR (1993) Alopecia universalis in an HIV-positive patient: possible insight into pathogenesis. J Cutan Pathol 20(2):180–183PubMedCrossRef Stewart MI, Smoller BR (1993) Alopecia universalis in an HIV-positive patient: possible insight into pathogenesis. J Cutan Pathol 20(2):180–183PubMedCrossRef
105.
go back to reference Sereti I, Sarlis NJ, Arioglu E, Turner ML, Mican JM (2001) Alopecia universalis and Graves’ disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS 15:138–140PubMedCrossRef Sereti I, Sarlis NJ, Arioglu E, Turner ML, Mican JM (2001) Alopecia universalis and Graves’ disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS 15:138–140PubMedCrossRef
106.
go back to reference Kunz M, Seifert B, Trüeb RM (2009) Seasonality of hair shedding in healthy women complaining of hair loss. Dermatology 219(2):105–110PubMedCrossRef Kunz M, Seifert B, Trüeb RM (2009) Seasonality of hair shedding in healthy women complaining of hair loss. Dermatology 219(2):105–110PubMedCrossRef
107.
go back to reference d’Ovidio R, d’Ovidio F (1995) Recidive stagionali dell’Alopecia Areata. G Ital Dermatol Venereol 295:130–134 d’Ovidio R, d’Ovidio F (1995) Recidive stagionali dell’Alopecia Areata. G Ital Dermatol Venereol 295:130–134
108.
go back to reference Thompson JM, Li T, Park MK, Qureshi AA, Cho E (2016) Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women. Arch Dermatol Res 308(9):671–676PubMedCrossRef Thompson JM, Li T, Park MK, Qureshi AA, Cho E (2016) Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women. Arch Dermatol Res 308(9):671–676PubMedCrossRef
109.
go back to reference Koo JY, Shellow WV, Hallman CP, Edwards JE (1994) Alopecia areata and increased prevalence of psychiatric disorders. Int J Dermatol 33(12):849–845PubMedCrossRef Koo JY, Shellow WV, Hallman CP, Edwards JE (1994) Alopecia areata and increased prevalence of psychiatric disorders. Int J Dermatol 33(12):849–845PubMedCrossRef
110.
go back to reference García-Hernández MJ, Ruiz-Doblado S, Rodriguez-Pichardo A, Camacho F (1999) Alopecia areata, stress and psychiatric disorders: a review. J Dermatol 26(10):625–632PubMedCrossRef García-Hernández MJ, Ruiz-Doblado S, Rodriguez-Pichardo A, Camacho F (1999) Alopecia areata, stress and psychiatric disorders: a review. J Dermatol 26(10):625–632PubMedCrossRef
111.
go back to reference Trüeb RM, Cavegn B (1996) Trichotillomania in connection with alopecia areata. Cutis 58:67–70PubMed Trüeb RM, Cavegn B (1996) Trichotillomania in connection with alopecia areata. Cutis 58:67–70PubMed
112.
113.
go back to reference Piraccini BM, Broccoli A, Starace M, Gaspari V, D’Antuono A, Dika E, Patrizi A (2015) Hair and scalp manifestations in secondary syphilis: epidemiology, clinical features and trichoscopy. Dermatology 231(2):171–176PubMedCrossRef Piraccini BM, Broccoli A, Starace M, Gaspari V, D’Antuono A, Dika E, Patrizi A (2015) Hair and scalp manifestations in secondary syphilis: epidemiology, clinical features and trichoscopy. Dermatology 231(2):171–176PubMedCrossRef
114.
go back to reference Ettefagh L, Nedorost S, Mirmirani P (2004) Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 140:1012PubMedCrossRef Ettefagh L, Nedorost S, Mirmirani P (2004) Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 140:1012PubMedCrossRef
115.
go back to reference Garcia Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, Blume-Peytavi U (2006) Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 142:1654–1655PubMedCrossRef Garcia Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, Blume-Peytavi U (2006) Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 142:1654–1655PubMedCrossRef
116.
go back to reference Chaves Y, Duarte G, Ben-Said B, Tebib J, Berard F, Nicolas JF (2008) Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 217:380PubMedCrossRef Chaves Y, Duarte G, Ben-Said B, Tebib J, Berard F, Nicolas JF (2008) Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 217:380PubMedCrossRef
117.
go back to reference Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N (2008) Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 216:320–323PubMedCrossRef Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N (2008) Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 216:320–323PubMedCrossRef
118.
go back to reference Fabre C, Dereure O (2008) Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 216:185–186PubMedCrossRef Fabre C, Dereure O (2008) Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 216:185–186PubMedCrossRef
119.
120.
121.
go back to reference Hernández MV, Nogués S, Ruiz-Esquide V, Alsina M, Cañete JD, Sanmartí R (2009) Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature. Clin Exp Rheumatol 27:892–893PubMed Hernández MV, Nogués S, Ruiz-Esquide V, Alsina M, Cañete JD, Sanmartí R (2009) Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature. Clin Exp Rheumatol 27:892–893PubMed
122.
go back to reference Doyle LA, Sperling LC, Baksh S, Lackey J, Thomas B, Vleugels RA, Qureshi AA, Velazquez EF (2011) Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol 33:161–166PubMedCrossRef Doyle LA, Sperling LC, Baksh S, Lackey J, Thomas B, Vleugels RA, Qureshi AA, Velazquez EF (2011) Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol 33:161–166PubMedCrossRef
123.
go back to reference Tauber M, Buche S, Reygagne P et al (2014) Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70:1146–1148PubMedCrossRef Tauber M, Buche S, Reygagne P et al (2014) Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70:1146–1148PubMedCrossRef
124.
go back to reference Tosti A, Bellavista S, Iorizzo M (2006) Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 55(3):438–441PubMedCrossRef Tosti A, Bellavista S, Iorizzo M (2006) Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 55(3):438–441PubMedCrossRef
125.
go back to reference Tan E, Tay YK, Goh CL, Chin GY (2002) The pattern and profile of alopecia areata in Singapore—a study of 219 Asians. Int J Dermatol 41(11):748–753PubMedCrossRef Tan E, Tay YK, Goh CL, Chin GY (2002) The pattern and profile of alopecia areata in Singapore—a study of 219 Asians. Int J Dermatol 41(11):748–753PubMedCrossRef
126.
go back to reference Yang S, Yang J, Liu JB, Wang HY, Yang Q, Gao M et al (2004) The genetic epidemiology of alopecia areata in China. Br J Dermatol 151(1):16–23PubMedCrossRef Yang S, Yang J, Liu JB, Wang HY, Yang Q, Gao M et al (2004) The genetic epidemiology of alopecia areata in China. Br J Dermatol 151(1):16–23PubMedCrossRef
127.
go back to reference Goh C, Finkel M, Christos PJ, Sinha AA (2006) Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 20(9):1055–1060PubMedCrossRef Goh C, Finkel M, Christos PJ, Sinha AA (2006) Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 20(9):1055–1060PubMedCrossRef
128.
go back to reference Brajac I, Tkalcic M, Dragojević DM, Gruber F (2003) Roles of stress, stress perception and trait-anxiety in the onset and course of alopecia areata. J Dermatol 30(12):871–878PubMedCrossRef Brajac I, Tkalcic M, Dragojević DM, Gruber F (2003) Roles of stress, stress perception and trait-anxiety in the onset and course of alopecia areata. J Dermatol 30(12):871–878PubMedCrossRef
129.
go back to reference Güleç AT, Tanriverdi N, Dürü C, Saray Y, Akçali C (2004) The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol 43(5):352–356PubMedCrossRef Güleç AT, Tanriverdi N, Dürü C, Saray Y, Akçali C (2004) The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol 43(5):352–356PubMedCrossRef
130.
go back to reference Manolache L, Benea V (2007) Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol 21(7):921–928PubMedCrossRef Manolache L, Benea V (2007) Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol 21(7):921–928PubMedCrossRef
131.
go back to reference Walker SA, Rothman S (1950) Alopecia areata. A statistical study and consideration of endocrine influences. J Invest Dermatol 14(6):403–413PubMedCrossRef Walker SA, Rothman S (1950) Alopecia areata. A statistical study and consideration of endocrine influences. J Invest Dermatol 14(6):403–413PubMedCrossRef
132.
go back to reference Meachen GN, Provis FL (1912) Alopecia areata et totalis cured by pregnancy, and relapsing with the re-establishment of the menses. Proc R Soc Med 5(Dermatol Sect):152–154PubMedPubMedCentral Meachen GN, Provis FL (1912) Alopecia areata et totalis cured by pregnancy, and relapsing with the re-establishment of the menses. Proc R Soc Med 5(Dermatol Sect):152–154PubMedPubMedCentral
133.
go back to reference Bakkerr JH, Seelen JC, Stolte LA, Verboom E (1956) Alopecia areata. Acta Endocrinol 23(1):60–71 Bakkerr JH, Seelen JC, Stolte LA, Verboom E (1956) Alopecia areata. Acta Endocrinol 23(1):60–71
134.
go back to reference Trüeb RM 2015. The difficult hair loss patient. Guide to successful management of alopecia and related conditions. Springer International Publishing AG Switzerland : pp. 89ff Trüeb RM 2015. The difficult hair loss patient. Guide to successful management of alopecia and related conditions. Springer International Publishing AG Switzerland : pp. 89ff
135.
go back to reference Abell E, Munro DD (1973) Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 88:55–59PubMedCrossRef Abell E, Munro DD (1973) Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 88:55–59PubMedCrossRef
136.
go back to reference Devi M, Rashid A, Ghafoor R (2015) Intralesional triamcinolone acetonide versus topical betamethasone valerate in the management of localized alopecia areata. J Coll Physicians Surg Pak 25(12):860–862PubMed Devi M, Rashid A, Ghafoor R (2015) Intralesional triamcinolone acetonide versus topical betamethasone valerate in the management of localized alopecia areata. J Coll Physicians Surg Pak 25(12):860–862PubMed
137.
go back to reference Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A (2011) Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichol 3(1):20–24CrossRef Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A (2011) Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichol 3(1):20–24CrossRef
138.
go back to reference Samrao A, Fu JM, Harris ST, Price VH (2013) Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. J Drugs Dermatol 12(2):e36–e40PubMed Samrao A, Fu JM, Harris ST, Price VH (2013) Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. J Drugs Dermatol 12(2):e36–e40PubMed
139.
go back to reference Chu TW, AlJasser M, Alharbi A, Abahussein O, McElwee K, Shapiro J (2015) Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study. J Am Acad Dermatol 73(2):338–340PubMedCrossRef Chu TW, AlJasser M, Alharbi A, Abahussein O, McElwee K, Shapiro J (2015) Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study. J Am Acad Dermatol 73(2):338–340PubMedCrossRef
140.
go back to reference Sharma VK (1996) Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 35(2):133–136PubMedCrossRef Sharma VK (1996) Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 35(2):133–136PubMedCrossRef
141.
go back to reference Sharma VK, Muralidhar S (1998) Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol 15(4):313–317PubMedCrossRef Sharma VK, Muralidhar S (1998) Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol 15(4):313–317PubMedCrossRef
142.
go back to reference Kar BR, Handa S, Dogra S, Kumar B (2005) Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 52(2):287–290PubMedCrossRef Kar BR, Handa S, Dogra S, Kumar B (2005) Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 52(2):287–290PubMedCrossRef
143.
go back to reference Agarwal A, Nath J, Barua KN (2006) Twice weekly 5 mg betamethasone oral pulse therapy in the treatment of alopecia areata. J Eur Acad Dermatol Venereol 20(10):1375–1376PubMedCrossRef Agarwal A, Nath J, Barua KN (2006) Twice weekly 5 mg betamethasone oral pulse therapy in the treatment of alopecia areata. J Eur Acad Dermatol Venereol 20(10):1375–1376PubMedCrossRef
144.
go back to reference Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH (1998) Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 39:597–602PubMedCrossRef Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH (1998) Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 39:597–602PubMedCrossRef
145.
go back to reference Nakajima T, Inui S, Itami S (2007) Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology 215:320–324PubMedCrossRef Nakajima T, Inui S, Itami S (2007) Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology 215:320–324PubMedCrossRef
146.
go back to reference Im M, Lee SS, Lee Y et al (2011) Prognostic factors in methylprednisolone pulse therapy for alopecia areata. J Dermatol 38(8):767–772PubMedCrossRef Im M, Lee SS, Lee Y et al (2011) Prognostic factors in methylprednisolone pulse therapy for alopecia areata. J Dermatol 38(8):767–772PubMedCrossRef
147.
go back to reference Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A (2016) A systematic review of pulse steroid therapy for alopecia areata. J Am Acad Dermatol 74(2):372–374PubMedCrossRef Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A (2016) A systematic review of pulse steroid therapy for alopecia areata. J Am Acad Dermatol 74(2):372–374PubMedCrossRef
148.
go back to reference Smith A, Trüeb RM, Theiler M, Hauser V, Weibel L (2015) High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr Dermatol 32(4):481–487PubMedCrossRef Smith A, Trüeb RM, Theiler M, Hauser V, Weibel L (2015) High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr Dermatol 32(4):481–487PubMedCrossRef
149.
go back to reference Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C (2003) Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 49:96–98PubMedCrossRef Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C (2003) Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 49:96–98PubMedCrossRef
150.
go back to reference Tosti A, Iorizzo M, Botta GL, Milani M (2006) Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 20:1243–1247PubMedCrossRef Tosti A, Iorizzo M, Botta GL, Milani M (2006) Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 20:1243–1247PubMedCrossRef
151.
152.
go back to reference Philpott MP, Sanders DA, Bowen J, Kealey T (1996) Effects of interleukines, colony-stimulating factor and tumor necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumor necrosis factor-a in alopecia areata. Br J Dermatol 135:942–948PubMedCrossRef Philpott MP, Sanders DA, Bowen J, Kealey T (1996) Effects of interleukines, colony-stimulating factor and tumor necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumor necrosis factor-a in alopecia areata. Br J Dermatol 135:942–948PubMedCrossRef
153.
go back to reference Hoffmann R, Happle R (1996) Topical immunotherapy in alopecia areata. What, how, and why? Dermatol Clin 14(4):739–744PubMedCrossRef Hoffmann R, Happle R (1996) Topical immunotherapy in alopecia areata. What, how, and why? Dermatol Clin 14(4):739–744PubMedCrossRef
154.
go back to reference Happle R, Kalveram KJ, Büchner U, Echternacht-Happle K, Göggelmann W, Summer KH (1980) Contact allergy as therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 161:289–297PubMedCrossRef Happle R, Kalveram KJ, Büchner U, Echternacht-Happle K, Göggelmann W, Summer KH (1980) Contact allergy as therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 161:289–297PubMedCrossRef
155.
go back to reference Shapiro J (1993) Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatol Clin 11(3):611–617PubMed Shapiro J (1993) Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatol Clin 11(3):611–617PubMed
156.
go back to reference Wilkerson MG, Henkin J, Wilkin JK, Smith RG (1985) Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 13:229–234PubMedCrossRef Wilkerson MG, Henkin J, Wilkin JK, Smith RG (1985) Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 13:229–234PubMedCrossRef
157.
go back to reference Tiwary AK, Mishra DK, Chaudhary SS (2016) Comparative study of efficacy and safety of topical squaric acid dibutylester and diphenylcyclopropenone for the treatment of alopecia areata. N Am J Med Sci 8(6):237–242PubMedPubMedCentralCrossRef Tiwary AK, Mishra DK, Chaudhary SS (2016) Comparative study of efficacy and safety of topical squaric acid dibutylester and diphenylcyclopropenone for the treatment of alopecia areata. N Am J Med Sci 8(6):237–242PubMedPubMedCentralCrossRef
158.
go back to reference Happle R, Hausen BM, Wiesner-Menzel L (1983) Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol 63(1):49–52PubMed Happle R, Hausen BM, Wiesner-Menzel L (1983) Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol 63(1):49–52PubMed
159.
go back to reference Hull SM, Norris J (1988) Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol 119(3):367–374PubMedCrossRef Hull SM, Norris J (1988) Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol 119(3):367–374PubMedCrossRef
160.
go back to reference Monk B (1989) Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol 14(2):154–157PubMedCrossRef Monk B (1989) Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol 14(2):154–157PubMedCrossRef
161.
go back to reference Pericin M, Trüeb RM (1998) Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology 196:418–421PubMedCrossRef Pericin M, Trüeb RM (1998) Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology 196:418–421PubMedCrossRef
162.
go back to reference Buckley DA, du Vivier AW (1999) Topical immunotherapy in dermatology. Int J Clin Pract 53(2):130–137PubMed Buckley DA, du Vivier AW (1999) Topical immunotherapy in dermatology. Int J Clin Pract 53(2):130–137PubMed
163.
go back to reference Bolduc C, Shapiro J (2000) DPCP for the treatment of alopecia areata. Skin Therapy Lett 5(5):3–4PubMed Bolduc C, Shapiro J (2000) DPCP for the treatment of alopecia areata. Skin Therapy Lett 5(5):3–4PubMed
164.
go back to reference Galadari I, Rubaie S, Alkaabi J, Galadari H (2003) Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Eur Ann Allergy Clin Immunol 35(10):397–401PubMed Galadari I, Rubaie S, Alkaabi J, Galadari H (2003) Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Eur Ann Allergy Clin Immunol 35(10):397–401PubMed
165.
go back to reference Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S (2001) The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 44(1):73–76PubMedCrossRef Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S (2001) The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 44(1):73–76PubMedCrossRef
166.
go back to reference Aghaei S (2005) Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol 5:6PubMedPubMedCentralCrossRef Aghaei S (2005) Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol 5:6PubMedPubMedCentralCrossRef
167.
go back to reference Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F (2007) Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 32(1):48–51PubMed Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F (2007) Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 32(1):48–51PubMed
168.
go back to reference El-Zawahry BM, Bassiouny DA, Khella A, Zaki N (2010) Five-year experience in the treatment of alopecia areata with DPC. J Eur Acad Dermatol Venereol 24(3):264–269PubMedCrossRef El-Zawahry BM, Bassiouny DA, Khella A, Zaki N (2010) Five-year experience in the treatment of alopecia areata with DPC. J Eur Acad Dermatol Venereol 24(3):264–269PubMedCrossRef
169.
go back to reference Ohlmeier MC, Traupe H, Luger TA, Böhm M (2012) Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata—a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol 26(4):503–507PubMedCrossRef Ohlmeier MC, Traupe H, Luger TA, Böhm M (2012) Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata—a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol 26(4):503–507PubMedCrossRef
170.
go back to reference Chiang KS, Mesinkovska NA, Piliang MP, Bergfeld WF (2015) Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc 17(2):50–55PubMedCrossRef Chiang KS, Mesinkovska NA, Piliang MP, Bergfeld WF (2015) Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc 17(2):50–55PubMedCrossRef
171.
go back to reference Hull SM, Pepall L, Cunliffe W (1991) Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 125(2):164–168PubMedCrossRef Hull SM, Pepall L, Cunliffe W (1991) Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 125(2):164–168PubMedCrossRef
172.
go back to reference Schuttelaar ML, Hamstra JJ, Plinck EP, Peereboom-Wynia JD, Vuzevski VD, Mulder PG, Oranje AP (1996) Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 135(4):581–585PubMedCrossRef Schuttelaar ML, Hamstra JJ, Plinck EP, Peereboom-Wynia JD, Vuzevski VD, Mulder PG, Oranje AP (1996) Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 135(4):581–585PubMedCrossRef
173.
go back to reference Katagiri K, Arakawa S, Hatano Y, Fujiwara S (2006) Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. J Dermatol 33(2):75–79PubMedCrossRef Katagiri K, Arakawa S, Hatano Y, Fujiwara S (2006) Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. J Dermatol 33(2):75–79PubMedCrossRef
174.
go back to reference Inui S, Nakajima T, Toda N, Itami S (2009) Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. J Dermatol 36(6):323–327PubMedCrossRef Inui S, Nakajima T, Toda N, Itami S (2009) Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. J Dermatol 36(6):323–327PubMedCrossRef
175.
go back to reference Joly P (2006) The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 55:632–636PubMedCrossRef Joly P (2006) The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 55:632–636PubMedCrossRef
176.
go back to reference Chartaux E, Joly P (2010) Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis. Ann Dermatol Venereol 137(8–9):507–513PubMedCrossRef Chartaux E, Joly P (2010) Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis. Ann Dermatol Venereol 137(8–9):507–513PubMedCrossRef
177.
go back to reference Kaelin U, Hassan AS, Braathen LR, Yawalkar N (2006) Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 55(3):529–532PubMedCrossRef Kaelin U, Hassan AS, Braathen LR, Yawalkar N (2006) Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 55(3):529–532PubMedCrossRef
178.
go back to reference Price VH, Hordinsky MK, Olsen EA et al (2008) Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol 58:395–402PubMedCrossRef Price VH, Hordinsky MK, Olsen EA et al (2008) Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol 58:395–402PubMedCrossRef
179.
go back to reference Major E (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61(1):35–47PubMedCrossRef Major E (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61(1):35–47PubMedCrossRef
180.
go back to reference Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13(6):337–339PubMedCrossRef Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13(6):337–339PubMedCrossRef
181.
go back to reference Robins DN (2007) Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy. J Drugs Dermatol 6(9):946–947PubMed Robins DN (2007) Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy. J Drugs Dermatol 6(9):946–947PubMed
182.
go back to reference Ali A, Martin JM IV. (2010) Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol 9(1):62–64PubMed Ali A, Martin JM IV. (2010) Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol 9(1):62–64PubMed
183.
go back to reference Lattouf C, Jimenez JJ, Tosti A et al (2015) Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol 72(2):359–361PubMedCrossRef Lattouf C, Jimenez JJ, Tosti A et al (2015) Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol 72(2):359–361PubMedCrossRef
184.
go back to reference Loi C, Starace M, Piraccini BM (2016) Alopecia areata (AA) and treatment with simvastatin/ezetimibe: experience of 20 patients. J Am Acad Dermatol 74(5):e99-eCrossRef Loi C, Starace M, Piraccini BM (2016) Alopecia areata (AA) and treatment with simvastatin/ezetimibe: experience of 20 patients. J Am Acad Dermatol 74(5):e99-eCrossRef
185.
go back to reference Freitas-Gouveia M, Trüeb RM (2017) Unsuccessful treatment of alopecia areata with simvastatin/ezetimibe: experience in 12 patients. Skin Appendage Disord 3:156–160PubMedCrossRef Freitas-Gouveia M, Trüeb RM (2017) Unsuccessful treatment of alopecia areata with simvastatin/ezetimibe: experience in 12 patients. Skin Appendage Disord 3:156–160PubMedCrossRef
186.
go back to reference Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O (1979) Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 115(10):1254–1255PubMedCrossRef Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O (1979) Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 115(10):1254–1255PubMedCrossRef
187.
go back to reference Fiedler-Weiss VC, Buys CM (1987) Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 123(11):1491–1493PubMedCrossRef Fiedler-Weiss VC, Buys CM (1987) Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 123(11):1491–1493PubMedCrossRef
188.
go back to reference Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL (1990) Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 126(6):756–759PubMedCrossRef Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL (1990) Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 126(6):756–759PubMedCrossRef
189.
go back to reference Olsen EA, Carson SC, Turney EA (1992) Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 128(11):1467–1467PubMedCrossRef Olsen EA, Carson SC, Turney EA (1992) Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 128(11):1467–1467PubMedCrossRef
190.
go back to reference Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS et al (1990) Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 22:242–250PubMedCrossRef Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS et al (1990) Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 22:242–250PubMedCrossRef
191.
go back to reference Paquest P, Arrase-Estrada J, Pierard GE (1992) Oral cyclosporine and alopecia areata. Dermatology 185:314–315CrossRef Paquest P, Arrase-Estrada J, Pierard GE (1992) Oral cyclosporine and alopecia areata. Dermatology 185:314–315CrossRef
192.
go back to reference Lee D, Oh DJ, Kim JW, Park SW, Oh MK, Sung HS, Hwang SW (2008) Treatment of severe alopecia areata: combination therapy using systemic cyclosporine a with low dose corticosteroids. Ann Dermatol 20(4):172–178PubMedPubMedCentralCrossRef Lee D, Oh DJ, Kim JW, Park SW, Oh MK, Sung HS, Hwang SW (2008) Treatment of severe alopecia areata: combination therapy using systemic cyclosporine a with low dose corticosteroids. Ann Dermatol 20(4):172–178PubMedPubMedCentralCrossRef
193.
go back to reference Yeo IK, Ko EJ, No YA et al (2015) Comparison of high-dose corticosteroid pulse therapy and combination therapy using oral cyclosporine with low-dose corticosteroid in severe alopecia Areata. Ann Dermatol 27(6):676–681PubMedPubMedCentralCrossRef Yeo IK, Ko EJ, No YA et al (2015) Comparison of high-dose corticosteroid pulse therapy and combination therapy using oral cyclosporine with low-dose corticosteroid in severe alopecia Areata. Ann Dermatol 27(6):676–681PubMedPubMedCentralCrossRef
194.
go back to reference Tosti A, Manuzzi P, Gasponi A (1988) Thymopentin in the treatment of severe alopecia areata. Dermatologica 177(3):170–174PubMedCrossRef Tosti A, Manuzzi P, Gasponi A (1988) Thymopentin in the treatment of severe alopecia areata. Dermatologica 177(3):170–174PubMedCrossRef
195.
196.
go back to reference Lowy M, Ledoux-Corbusier M, Achten G, Wybran J (1985) Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies. J Am Acad Dermatol 12(1 Pt 1):78–84PubMedCrossRef Lowy M, Ledoux-Corbusier M, Achten G, Wybran J (1985) Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies. J Am Acad Dermatol 12(1 Pt 1):78–84PubMedCrossRef
197.
198.
go back to reference Georgala S, Katoulis AC, Befon A, Georgala K, Stavropoulos PG (2006) Inosiplex for treatment of alopecia areata: a randomized placebo-controlled study. Acta Derm Venereol 86(5):422–424PubMedCrossRef Georgala S, Katoulis AC, Befon A, Georgala K, Stavropoulos PG (2006) Inosiplex for treatment of alopecia areata: a randomized placebo-controlled study. Acta Derm Venereol 86(5):422–424PubMedCrossRef
199.
go back to reference Mrowietz U, Christophers E, Altmeyer P (1999) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 141(3):424–429PubMedCrossRef Mrowietz U, Christophers E, Altmeyer P (1999) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 141(3):424–429PubMedCrossRef
200.
go back to reference Venten I, Hess N, Hirschmüller A, Altmeyer P, Brockmeyer N (2006) Treatment of therapy-resistant alopecia areata with fumaric acid esters. Eur J Med Res 11(7):300–305PubMed Venten I, Hess N, Hirschmüller A, Altmeyer P, Brockmeyer N (2006) Treatment of therapy-resistant alopecia areata with fumaric acid esters. Eur J Med Res 11(7):300–305PubMed
201.
go back to reference Healy E, Rogers S (1993) PUVA treatment for alopecia areata—does it work? A retrospective review of 102 cases. Br J Dermatol 129(1):42–44PubMedCrossRef Healy E, Rogers S (1993) PUVA treatment for alopecia areata—does it work? A retrospective review of 102 cases. Br J Dermatol 129(1):42–44PubMedCrossRef
202.
go back to reference Taylor CR, Hawk JL (1995) PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol 133(6):914–918PubMedCrossRef Taylor CR, Hawk JL (1995) PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol 133(6):914–918PubMedCrossRef
203.
go back to reference Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J (2010) Hypnosis in refractory alopecia areata significantly improves depression, anxiety, and life quality but not hair regrowth. J Am Acad Dermatol 62(3):517–518PubMedCrossRef Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J (2010) Hypnosis in refractory alopecia areata significantly improves depression, anxiety, and life quality but not hair regrowth. J Am Acad Dermatol 62(3):517–518PubMedCrossRef
204.
go back to reference Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F (2013) A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 169(3):690–694PubMedCrossRef Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F (2013) A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 169(3):690–694PubMedCrossRef
205.
go back to reference Waldmann TA (2013) The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Invest Dermatol Symp Proc 16:S28–S30CrossRef Waldmann TA (2013) The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Invest Dermatol Symp Proc 16:S28–S30CrossRef
206.
go back to reference Falto-Aizpurua L, Choudhary S, Tosti A (2014) Emerging treatments in alopecia. Expert Opin Emerg Drugs 19(4):545–556PubMedCrossRef Falto-Aizpurua L, Choudhary S, Tosti A (2014) Emerging treatments in alopecia. Expert Opin Emerg Drugs 19(4):545–556PubMedCrossRef
207.
go back to reference Divito SJ, Kupper TS (2014) Inhibiting Janus kinases to treat alopecia areata. Nat Med 20(9):989–990PubMedCrossRef Divito SJ, Kupper TS (2014) Inhibiting Janus kinases to treat alopecia areata. Nat Med 20(9):989–990PubMedCrossRef
208.
go back to reference Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia areata universalis in a patient with plaque psoriais. J Invest Dermatol 134(12):2988–2990PubMedCrossRef Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia areata universalis in a patient with plaque psoriais. J Invest Dermatol 134(12):2988–2990PubMedCrossRef
209.
go back to reference Xing L, Dai Z, Jabbari A et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043–1049PubMedPubMedCentralCrossRef Xing L, Dai Z, Jabbari A et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043–1049PubMedPubMedCentralCrossRef
210.
go back to reference Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A (2015) Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2(4):351–355PubMedPubMedCentralCrossRef Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A (2015) Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2(4):351–355PubMedPubMedCentralCrossRef
211.
go back to reference Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76(1):22–28PubMedCrossRef Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76(1):22–28PubMedCrossRef
212.
go back to reference Craiglow BG, Liu LY, King BA (2017) Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol 76(1):29–32PubMedCrossRef Craiglow BG, Liu LY, King BA (2017) Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol 76(1):29–32PubMedCrossRef
213.
go back to reference Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, Navarini AA (2016) Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol 8(1):102–106PubMedPubMedCentralCrossRef Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, Navarini AA (2016) Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol 8(1):102–106PubMedPubMedCentralCrossRef
214.
go back to reference Brunne V, Mertins G, Reimann G, Brockmeyer NH (2004) Off-label use in dermatological practice. The conflict between professional duty and legal requirements. Hautarzt 55(8):727–734PubMedCrossRef Brunne V, Mertins G, Reimann G, Brockmeyer NH (2004) Off-label use in dermatological practice. The conflict between professional duty and legal requirements. Hautarzt 55(8):727–734PubMedCrossRef
Metadata
Title
Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
Authors
Ralph M. Trüeb
Maria Fernanda Reis Gavazzoni Dias
Publication date
01-02-2018
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2018
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-017-8620-9

Other articles of this Issue 1/2018

Clinical Reviews in Allergy & Immunology 1/2018 Go to the issue